Table 3.

Univariate Analysis of Mortality Within 90 Days in 147 Human Immunodeficiency Virus-Uninfected Patients With Cryptococcosis

Variable	No. (%) of Patients Who Died (n = 48)	No. (%) of Patients Who Survived (n = 99)	Hazard Ratio (95% CI)	P Value
ID consultation	27 (56)	73 (73)	0.49 (.28–.87)	.014
Age >55 y	40 (83)	48 (49)	3.9 (1.9–8.5)	<.001
Male sex	38 (79)	63 (64)	1.8 (.9–3.7)	.086
Race
White	39 (81)	79 (80)	b
African American	8 (17)	10 (10)	1.6 (.7–3.4)	.23
Other	1 (2)	10 (10)	0.25 (.4–1.8)	.170
Site of infection
Central nervous system	17 (35)	45 (46)	0.70 (.4–1.2)	.25
Pulmonary	17 (35)	40 (4)	0.9 (.5–1.6)	.62
Bloodstream	27 (56)	31 (31)	2.4 (1.4–4.3)	.003
Other	3 (6)	7 (7)	0.9 (.3–2.8)	.82
Disseminated disease	39 (81)	63 (64)	2.2 (1.1–4.5)	.036
Positive serum CrAg	43 (90)	65 (66)	3.6 (1.4–9.2)	.006
Serum CrAg titer
0	3 (6)	34 (34)	b
1:1–1:8	4 (8)	7 (7)	5.3 (1.2–23.8)	.028
1:16–1:512	31 (65)	48 (49)	5.9 (1.8–19.2)	.003
≥1:1204	10 (21)	10 (10)	8.5 (2.3–30.8)	.001
Positive CSF CrAg	16 (64)	44 (69)	0.9 (.4–2.0)	.80
CSF CrAg titera
0	9 (36)	20 (30)	b	.44
1:2–1:8	4 (16)	16 (24)	0.7 (.2–2.3)	.57
1:16–1:512	6 (24)	22 (33)	0.7 (.3–2.0)	.51
≥1:1024	6 (24)	8 (12)	1.7 (.6–4.0)	.34
Predisposing factors
None	6 (13)	28 (28)	0.41 (.17–.96)	.039
Chemotherapy	18 (38)	13 (13)	2.7 (1.5–4.8)	.001
Hematologic malignancy	12 (25)	13 (13)	1.9 (.99–3.6)	.055
End-stage renal disease	3 (6)	6 (6)	0.97 (.30–3.1)	.97
End-stage liver disease	13 (27)	9 (9)	3.0 (1.6–5.8)	.001
Solid organ transplant	4 (8)	20 (20)	0.41 (.14–1.1)	.088
Glucocorticoid therapy	12 (25)	35 (35)	0.66 (.34–1.3)	.21
Biologic therapy	3 (6)	9 (9)	0.65 (.20–2.1)	.47
Other immunosuppressive therapy	7 (15)	18 (18)	0.77 (.35–1.7)	.52

Abbreviations: CI, confidence interval; CrAg, cryptococcal antigen; CSF, cerebrospinal fluid; ID, infectious disease; y, year.

^aPercentages were calculated of 91 that received lumbar punctures.

^bReference category.